PLX vs SPRB
PLX: A rare-disease biopharmaceutical company with a proprietary plant cell-based protein expression platform and two FDA/EMA-approved enzyme replacement therapies for lysosomal storage disorders. SPRB: Clinical-stage biopharmaceutical company developing tralesinidase alfa enzyme replacement therapy for rare lysosomal storage disorders, particularly Sanfilippo Syndrome Type B.
Side-by-side fundamentals
| Metric | PLX | SPRB | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $2.37 | $44.60 | |
| Market cap as of 2026-07-23 | $190M | $123M | |
| P/E as of 2026-07-23 | 12.40 | n/a | |
| PEG as of 2026-07-23 | 0.04 | n/a | |
| Net margin as of 2026-07-23 | +20.1% | -1079.9% | PLX higher |
| Gross margin as of 2026-07-23 | +70.0% | n/a | |
| Operating margin as of 2026-07-23 | +25.9% | -1143.4% | PLX higher |
| ROE as of 2026-07-23 | +28.1% | -155.4% | PLX higher |
| ROA as of 2026-07-23 | +17.8% | -101.7% | PLX higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.19 | PLX lower |
| Revenue growth (YoY) as of 2026-07-23 | +27.8% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +3.5% | n/a | |
| Beta as of 2026-07-23 | -0.00 | 3.45 | |
| 1-year return as of 2026-07-22 close | +50.0% | +423.9% | SPRB higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.